RNA as a target for small-molecule therapeutics

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 1, 2005, Pages 49-62

  Hermann, Thomas ^a   Tor, Yitzhak ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aminoglycosides; HIV; Ribosome; RNase P; X ray crystallography

Indexed keywords

2 AMINOPYRIDINE DERIVATIVE; 2 AMINOQUINOLINE; 2 DEOXYSTREPTAMINE; 4 HYDROXY 2 QUINOLONE 3 CARBOXYLIC ACID AMIDE; AMIDINOHYDRAZONE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL RNA; BETA CARBOLINE DERIVATIVE; CHLORAMPHENICOL; ERYTHROMYCIN; ESTERASE INHIBITOR; FRAMYCETIN; KANAMYCIN DERIVATIVE; KETOLIDE; LINEZOLID; MACROLIDE; N (AMINOETHYL) 4 METHYL 2 AMINOPYRIDINE; NEAMINE; OXAZOLIDINEDIONE DERIVATIVE; PAROMOMYCIN; PROFLAVINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REV PROTEIN; RIBONUCLEASE P; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; THIOSTREPTON; TREHALOSE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA;

BINDING AFFINITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; GENE TARGETING; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL LITERATURE; MOLECULAR RECOGNITION; NONHUMAN; REVIEW; RIBOSOME; RNA STRUCTURE; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

EID: 13544264777     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.1.49     Document Type: Review

References (104)

1. HERMANN T, WESTHOF E: RNA as a drug target: chemical, modelling and evolutionary tools. Curr. Opin. Biotechnol. (1998) 9:66-73.
2. HERMANN T: Strategies for the design of drugs targeting RNA and RNA-protein complexes. Angew. Chem. Int. Ed. (2000) 39 1890-1904.
3. TOR Y: Targeting RNA with small molecules. Chembiochem (2003) 4:998-1007.
4. MANDAL M, BREAKER RR: Gene regulation by riboswitches. Nat. Rev. Mol. Cell Biol. (2004) 5:451-463.
5. NUDLER E, MIRONOV AS: The riboswitch control of bacterial metabolism. Trends Biochem. Sci. (2004) 29:11-17.
6. AUERBACH T, BASHAN A, SCHLUENZEN J et al.: Antibiotics targeting ribosomes: crystallographic studies. Curr. Drug Targets Infect. Disord. (2002) 2:169-186.
7. HERMANN T: Chemical and functional diversity of small molecule ligands for RNA. Biopolymers (2003) 70:4-18.
8. GRIFFEY RH, SWAYZE EE: RNA-targeted therapeutics: prospects and promise. Expert Opin. Ther. Patents (2002) 12:1367-1374.
9. VICENS Q, WESTHOF E: RNA as a drug target: the case of aminoglycosides. Chembiochem (2003) 4:1018-1023.
10. POEHLSGAARD J, DOUTHWAITE S: Macrolide antibiotic interaction and resistance on the bacterial ribosome. Curr. Opin. Investig. Drugs (2003) 4:140-148.
11. DRYSDALE MJ, LENTZEN G, MATASSOVA N, MURCHIE AI, ABOUL-ELA F, AFSHAR M: RNA as a drug target. Prog. Med. Chem. (2002) 39 73-119.
12. HADDAD J, KOTRA LP, LLANO-SOLETO B et al.: Design of novel antibiotics that bind to the ribosomal acyltransferase site. J. Am. Chem. Soc. (2002) 124:3229-3237.
13. RUSSELL RJ, MURRAY JB, LENTZEN G, HADDAD J, MOBASHERY S: The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J. Am. Chem. Soc. (2003) 125:3410-3411.
14. FRIDMAN M, BELAKHOV V, YARON S, BAASOV T: A new class of branched aminoglycosides: pseudopentasaccharide dervatives of beomycin B. Org. Lett. (2003) 5:3575-3578.
15. DING Y, HOFSTADLER SA, SWAYZE EE, GRIFFEY RH: An efficient synthesis of mimetics of neamine for RNA recognition. Org. Lett. (2001) 3:1621-1623.
16. DING Y, HOFSTADLER SA, SWAYZE EE, RISEN L, GRIFFEY RH: Design and synthesis of paromomycin-related heterocycle-substituted aminoglycoside mimetics based on a mass spectrometry RNA-binding assay. Angew. Chem. Int. Ed. (2003) 42:3409-3412.
17. YAO S, SGARBI PW, MARBY KA et al.: Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. Bioorg. Med. Chem. Lett. (2004) 14:3733-3738.
18. VOURLOUMIS D, TAKAHASHI M, WINTERS GC et al.: Novel 2,5-dideoxystreptamine derivatives taregting the ribosomal decoding site RNA. Bioorg. Med. Chem. Lett. (2002) 12:3367-3372.
19. SIMONSEN KB, AYIDA BK, VOURLOUMIS D et al.: Novel paromamine derivatives exploring shallow-groove recognition of ribosomal-decoding-site RNA. Chembiochem (2002) 3:1223-1228.
20. VOURLOUMIS D, WINTERS GC, TAKAHASHI M et al.: Novel acyclic deoxystreptamine mimetics targeting the ribosomal decoding site. Chembiochem (2003) 4:879-885.
21. SIMONSEN KB, AYIDA BK, VOURLOUMIS D et al.: Piperidine glycosides targeting the ribosomal decoding site. Chembiochem (2003) 4:886-890.
22. BARLUENGA S, SIMONSEN KB, LITTLEFIELD ES et al.: Rational design of azepane-glycoside antibiotics targteing the bacterial ribosome. Bioorg. Med. Chem. Lett. (2004) 14:713-718.
23. VICENS Q, WESTHOF E: Molecular recognition of aminoglycoside antibiotics by ribosomal RNA and resistance enzymes: an analysis of X-ray crystal structures. Chembiochem (2003) 4:1018-1023.
24. WU B, YANG J, ROBINSON D et al.: Synthesis of linked carbohydrates and evaluation of their binding for 16S RNA by mass spectrometry. Bioorg. Med. Chem. Lett. (2003) 13:3915-3918.
25. AGNELLI F, SUCHECK SJ, MARBY KA et al.: Dimeric aminoglycosides as antibiotics. Angew. Chem. Int. Ed. (2004) 43 1562-1566.
26. CHOU CH, WU CS, CHEN CH et al.: Regioselective glycosylation of neamine core: a facile entry to kanamycin B related analogues. Org. Lett. (2004) 6:585-588.
27. HE Y, YANG J, WU B et al.: Synthesis and evaluation of novel bacterial rRNA-binding benzimidazoles by mass spectrometry. Bioorg. Med. Chem. Lett. (2004) 14:695-699.
28. SWAYZE EE, JEFFERSON EA, SANNES-LOWERY KA et al.: SAR by MS: A ligand based technique for drug lead discovery against structured RNA targets. J. Med. Chem. (2002) 45:3816-3819.
29. YU L, OOST TK, SCHKERYANTZ JM, YANG J, JANOWICK D, FESIK SW: Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J. Am. Chem. Soc. (2003) 125 4444-4450.
30. JOHNSON EC, FEHER VA, PENG JW, MOORE JM, WILLIAMSON JR: Application of NMR SHAPES screening to an RNA target. J. Am. Chem. Soc. (2003) 125:15724-15725.
31. FOLOPPE N, CHEN I-J, DAVIS B, HOLD A, MORLEY D, HOWES R: A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site. Bioorg. Med. Chem. (2004) 12 935-947.
32. DISNEY MD, SEEBERGER PH: Aminoglycoside microarrays to explore interactions of antibiotics with RNAs and proteins. Chemistry (2004) 10:3308-3314.
33. KAUL M, BARBIERI CM, PILCH DS: Fluorescence-based approach for detecting and characterizing antibiotic-induced conformational changes in ribosomal RNA: comparing aminoglycoside binding to prokaryotic and eukaryotic ribosomal RNA sequences. J. Am. Chem. Soc. (2004) 126:3447-3453.
34. SHANDRICK S, ZHAO Q, HAN Q et al.: Monitoring molecular recognition of the ribosomal decoding site. Angew. Chem. Int. Ed. (2004) 43:3177-3182.
35. MATASSOVA NB, RODNINA MV, ENDERMANN R et al.: Ribosomal RNA is the target for oxazolidinones, a novel class of translation inhibitors. RNA (1999) 5:939-946.
36. H Nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob. Agents Chemother. (2002) 46:625-629.
37. AOKI H, KE L, POPPE SM et al.: Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob. Agents Chemother. (2002) 46:1080-1085.
38. HANSEN JL, IPPOLITO JA, BAN N, NISSEN P, MOORE PB, STEITZ TA: The structures of four macrolide antibiotics bound to the large ribosomal subunit. Molecular Cell (2002) 10:117-128.
39. LENTZEN G, KLINCK R, MATASSOVA N, ABOUL-ELA F: Structural basis for contrasting activities of ribosome binding thiazole antibiotics. Chem. Biol. (2003) 10:769-778.
40. BOWER J, DRYSDALE M, HEBDON R et al.: Structure-based design of agents targeting the bacterial ribosome. Bioorg. Med. Chem. Lett. (2003) 13:2455-2458.
41. LEE J, KWON M, LEE KH et al.: An approach to enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid). J. Am. Chem. Soc. (2004) 126 1956-1957.
42. CARRIERE M, VIJAYABASKAR V, APPLEFIEID D et al.: Inhibition of protein synthesis by aminoglycoside-argirinine conjugates. RNA (2002) 8:1267-1279.
43. DANDLIKER PJ, PRATT SD, NILIUS AM et al.: Novel antibacterial class. Antimicrob. Agents Chemother. (2003) 47 3831-3839.
44. JEFFERSON EA, ARAKAWA S, BLYN LB et al.: New inhibitors of bacterial protein synthesis from a combinatorial library of macrocycles. J. Med. Chem. (2002) 45:3430-3439.
45. PRATT SD, DAVID CA, BLACK-SCHAEFER C et al.: A strategy for discovery of novel broad-spectrum antibacterials using a high-throughput Streptococcus pneumoniae transcription/translation screen. J. Biomol. Screen. (2004) 9:3-11.
46. CLARK RF, WANG S, MA, Z et al.: Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphtyridine derivatives incorporating position 3 and 4 variants. Bioorg. Med Chem. Lett. (2004) 14:3299-3302.
47. JEFFERSON EA, ARAKAWA S, BLYN LB et al.: New inhibitors of bacterial protein synthesis from a combinatorial library of macrocycles.J. Med. Chem. (2002) 45:3430-3439.
48. VIOQUE A, DE LA CRUZ J: Trans-translation and protein synthesis inhibitors. FEMS Microbiol. Lett. (2003) 218:9-14.
49. CORVAISIER S, BORDEAU V, FELDEN B: Inhibition of transfer messenger RNA aminoacylation and trans-translation by aminoglycoside antibiotics. J. Biol. Chem. (2003) 278 14788-14797.
50. TAKAHASHI T, KONNO T, MUTO A, HIMENO H: Various effects of paromomycin on tmRNA-directed trans-translation. J. Biol. Chem. (2003) 278:27672-27680.
51. KONNO T, TAKAHASHI T, KURITA D, MUTO A, HIMENO H: A minimum structure of aminoglycosides that causes an initiation shift trans translation. Nucleic Acids Res. (2004) 32:4119-4126.
52. MIKKELSEN NE, BRANNVALL M, VIRTANEN A, KIRSEBOM LA: Inhibition of RNAse P RNA cleavage by aminoglycosides. Proc. Natl. Acad. Sci. USA (1999) 96:6155-6160.
53. EDER PS, HATFIELD C, VIOQUE A, GOPALAN V: Bacterial RNase P as a potential target for novel anti-infectives. Curr. Opin. Investig. Drugs (2003) 4:937-943.
54. EUBANK TD, BISWAS R, JOVANOVIC M, LITOVCHICK A, LAPIDOT A, GOPALAN V: Inhibition of bacterial RNase P by aminoglycoside-arginine conjugates. FEBS Lett. (2002) 511:107-112.
55. ZAPP ML, STERN S, GREEN MR: Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell (1993) 74:969-978.
56. WERSTUCK G, ZAPP ML, GREEN MR: A non-canonical base pair within the human immunodeficiency virus revresponsive element is involved in both rev and small molecule recognition. Chem. Biol. (1996) 3 129-137.
57. MEI HY, MACK DP, GALAN AA et al.: Discovery of selective, small-molecule inhibitors of RNA complexes I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. Bioorg. Med. Chem. (1997) 5:1173-1184.
58. MCKNIGHT KL, HEINZ BA: RNA as a target for developing antivirals. Antivir. Chem. Chemother. (2003) 14:61-73.
59. FROEYEN M, HERDEWIJN P: RNA as a target for drug design, the example of Tat-TAR interaction. Curr. Top. Med. Chem. (2002) 2 1123-1145.
60. BABA M: Inhibitors of HIV-1 gene expression and transcription. Curr. Top. Med. Chem. (2004) 4:871-882.
61. LUEDTKE NW, TOR Y: Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 Rev-RRE inhibitors. Biopolymers (2003) 70:103-119.
62. LUEDTKE NW, LIU Q, TOR Y: RNA-ligand interactions: affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev response element. Biochemistry (2003) 42 11391-11403.
63. LUEDTKE NW, LIU Q, TOR Y: Synthesis, photophysical properties, and nucleic acid binding of phenanthridinium derivatives based on ethidium. Chembiochem (2003) 11:5235-5247.
64. LUEDTKE NW, BAKER TJ, GOODMAN M, TOR Y: Guanidinoglycosides: a novel family of RNA ligands. J. Am. Chem. Soc. (2000) 122 12035-12036.
65. LUEDTKE NW, CARMICHAEL P, TOR Y: Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine. J. Am. Chem. Soc. (2003) 125:12374-12375.
66. BAKER TJ, LUEDTKE NW, TOR Y, GOODMAN M: Synthesis and anti-HIV activity of guanidinoglycosides. J. Org. Chem. (2000) 65:9054-9058.
67. LACOURCIERE KA, STIVERS JT, MARINO JP: Mechanism of neomycin and Rev peptide binding to the Rev responsive element of HIV-1 as determined by fluorescence and NMR spectroscopy. Biochemistry (2000) 39:5630-5641.
68. DEJONG ES, CHANG C, GILSON MK, MARINO JP: Proflavine as a Rev inhibitor by targeting the high-affinity Reb binding site of the Rev responsive element of HIV-1. Biochemistry (2003) 42 8035-8046.
69. CHAPMAN RL, STANLEY TB, HAZEN R, GARVEY EP: Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening Antiviral Res. (2002) 54:149-162.
70. TAO J, FRANKEL AD: Specific binding of arginine to TAR RNA. Proc. Natl. Acad. Sci. USA (1992) 89:2723-2726.
71. BLOUNT KF, TOR Y: Using pyrene-labeled HIV-1 TAR to measure RNA-small molecule binding. Nucleic Acids Res. (2003) 31 5490-5500.
72. BRADICK TD, MARINO JP: Ligand-induced changes in 2-aminopurine fluorescence as a probe for small molecule binding to HIV-1 TAR RNA. RNA (2004) 10:1459-1468.
73. HAMY F, FELDER E, LIPSON K, KLIMKAIT T: Merged screening for human immunodeficiency virus Tat and Rev inhibitors. J. Biomol. Screen. (2001) 6:179-187.
74. WANG M, XU Z, TU P, YU X, XIA S, YANG M: α,α-Trehalose derivatives bearing guanidino groups as inhibitors to HIV-1 Tat-TAR RNA interaction in human cells. Bioorg. Med. Chem. Lett. (2004) 14 2585-2588.
75. YU X, LIN W, LI J, YANG M: Synthesis and biological evaluation of novel α-carboline derivatives as Tat-TAR interaction inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:3127-3130.
76. HERMANN T, WESTHOF E: Exploration of metal ion binding sites in RNA folds by Brownian-dynamics simulations. Structure (1998) 6:1303-1314.
77. HERMANN T, WESTHOF E: Docking of cationic antibiotics to negatively charged pockets in RNA folds. J. Med. Chem. (1999) 42 1250-1261.
78. DAVIS B, AFSHAR M, VARANI G et al.: Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic 'hot spots'. J. Mol. Biol. (2004) 336:343-356.
79. MURCHIE AIH, DAVIS B, ISEL C et al.: Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. (2004) 336 625-638.
80. HERMANN T: Rational ligand design for RNA: the role of static structure and conformational flexibility in target recognition. Biochimie (2002) 84:869-875.
81. LIND KE, DU Z, FUJINAGA K, PETERLIN BM, JAMES TL: Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol. (2002) 9:185-193.
82. DU Z, LIND KE, JAMES TL: Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. Chem. Biol. (2002) 9:707-712.
83. MAYER M, JAMES TL: NMR-based characterization of phenothiazines as a RNA binding scaffold. J. Am. Chem. Soc. (2004) 126:4453-4460.
84. HAMY F, BRONDANI V, FLORSHEIMER A, STARK W, BLOMMERS MJ, KLIMKAIT T: A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. Biochemistry (1998) 37:5086-5095.
85. GAYLE AY, BARANGER AM: Inhibition of the U1A-RNA complex by an aminoacridine derivative. Bioorg. Med. Chem. Lett. (2002) 12 2839-2842.
86. CECCHETTI V, PAROLIN C, MORO S et al.: 6-Aminoquinolones as new potential anti-HIV agents. J. Med. Chem. (2000) 43:3799-3802.
87. PAROLIN C, GATTO B, DEL VECCHIO C et al.: New anti-HIV Type 1 6-aminoquinolones: mechanism of action. Antimicrob. Agents Chemother. (2003) 47:889-896.
88. RICHTER S, PAROLIN C, GATTO B et al.: Inhibition of human inummodeficiency virus Type 1 Tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob. Agents Chemother. (2004) 48:1895-1899.
89. RICHTER S, PAROLIN C, PALUMBO M, PALU G: Antiviral properties of quinolone-based drugs. Curr. Drug Targets Infect. Disord. (2004) 4:111-116.
90. ENNIFAR E, PAILLART JC, MARQUET R et al.: HIV-1 RNA dimerization initiation site is structurally similar to the ribosomal A site and binds aminoglycoside antibiotics. J. Biol. Chem. (2003) 278:2723-2730.
91. MCPIKE MP, GOODISMAN J, DABROWIAK JC: Footprinting and circular dichroism studies on paromomycin binding to the packaging region of human immunodeficiency virus type-1. Bioorg. Med. Chem. (2002) 10:3663-3672.
92. MCPIKE MP, GOODISMAN J, DABROWIAK JC: Specificity of neomycin analogues bound to the packaging region of human immunodficiency virus type 1 RNA. Bioorg. Med. Chem. (2004) 12:1835-1843.
93. COHEN J: Chiron stakes out its teritory. Science (1999) 285:28.
94. GALLEGO J, VARANI G: The hepatitis C virus internal ribosome-entry site: a new target for antiviral research. Biochem. Soc. Trans. (2002) 30:140-145.
95. JUBIN R: Targeting hepatitis C virus translation: stopping HCV where its starts. Curr. Opin. Investig. Drugs (2003) 4 162-167.
96. SPAHN CM, KIEFT JS, GRASSUCI RA et al.: Hepatitis C virus IRES RNA-induced changes in the conformation of the 40S ribosomal subunit. Science (2001) 291:1959-1962.
97. KLINCK R, WESTHOF E, WALKER S, AFSHAR M, COLLIER A, ABOUL-ELA F: A potential RNA drug target in the hepatitis C virus internal ribosome entry site. RNA (2000) 6:1423-1431.
98. LUKAVSKY PJ, OTTO GA, LANCASTER AM, SARNOW P, PUGLISI JD: Structures of two RNA domains essential for hepatitis C virus internal ribosome entry site function. Nat. Struct. Biol. (2000) 7 1105-1110.
99. KIEFT JS, ZHOU K, GRECH A, JUBIN R, DOUDNA JA: Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. Nat. Struct. Biol. (2002) 9:370-374.
100. KIM I, LUKAVSKY PJ, PUGLISI JD: NMR study of 100 kDa HCV IRES RNA using segmental isotope labeling. J. Am. Chem. Soc. (2002) 124:9338-9339.
101. LUKAVSKY PJ, KIM I, OTTO GA, PUGLISI JD: Structure of HCV IRES domain II determined by NMR. Nat. Struct. Biol. (2003) 10 1033-1038.
102. GOODING KB, HIGGS R, HODGE B et al.: High throughput screening of library compounds against an oligonucleotide substructure of an RNA target. J. Am. Soc. Mass Spectrom. (2004) 15:884-892.
103. JEFFERSON EA, SETH PP, ROBINSON DE et al.: Biaryl guanidine inhibitors of in vitro HCV-IRES activity. Bioorg. Med. Chem. Lett. (2004), 14:5139-5143.
104. SCHMID MB: Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nat. Rev. Microbiol. (2004) 2:739-746.